News

Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...
Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...
The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...
The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...
A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...
Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...
The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...
Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...
The US Food and Drug Administration (FDA) accepted Novo Nordisk’s New Drug Application (NDA) submission for an ...